Granite Investment Partners LLC raised its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.6% during the second quarter, Holdings Channel reports. The institutional investor owned 482,962 shares of the specialty pharmaceutical company’s stock after buying an additional 12,163 shares during the period. Supernus Pharmaceuticals makes up 1.4% of Granite Investment Partners LLC’s portfolio, making the stock its 5th largest position. Granite Investment Partners LLC’s holdings in Supernus Pharmaceuticals were worth $20,816,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of SUPN. BlackRock Inc. raised its position in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares during the last quarter. Vanguard Group Inc. raised its position in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock worth $78,762,000 after buying an additional 156,094 shares during the last quarter. Bank of New York Mellon Corp raised its position in Supernus Pharmaceuticals by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock worth $52,236,000 after buying an additional 78,084 shares during the last quarter. Ranger Investment Management L.P. raised its position in Supernus Pharmaceuticals by 2.8% in the first quarter. Ranger Investment Management L.P. now owns 1,482,535 shares of the specialty pharmaceutical company’s stock worth $46,403,000 after buying an additional 40,131 shares during the last quarter. Finally, State Street Corp raised its position in Supernus Pharmaceuticals by 4.0% in the first quarter. State Street Corp now owns 1,355,319 shares of the specialty pharmaceutical company’s stock worth $42,422,000 after buying an additional 52,091 shares during the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 41.20 on Thursday. The firm has a 50-day moving average of $42.60 and a 200 day moving average of $33.95. Supernus Pharmaceuticals, Inc. has a 12 month low of $17.25 and a 12 month high of $44.95. The company has a market cap of $2.08 billion, a price-to-earnings ratio of 20.80 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The firm had revenue of $75.83 million for the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. On average, analysts expect that Supernus Pharmaceuticals, Inc. will post $1.03 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Raised by Granite Investment Partners LLC” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/supernus-pharmaceuticals-inc-nasdaqsupn-position-raised-by-granite-investment-partners-llc.html.

SUPN has been the topic of a number of recent analyst reports. Piper Jaffray Companies raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the company from $30.00 to $44.00 in a research report on Thursday, June 1st. Jefferies Group LLC raised their price target on shares of Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. Cantor Fitzgerald raised their price target on shares of Supernus Pharmaceuticals from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, May 11th. Cowen and Company raised their price target on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, May 11th. Finally, Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $48.43.

In other news, VP Padmanabh P. Bhatt sold 2,500 shares of the firm’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $35.90, for a total transaction of $89,750.00. Following the sale, the vice president now owns 37,500 shares of the company’s stock, valued at approximately $1,346,250. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $39.86, for a total transaction of $398,600.00. Following the sale, the vice president now directly owns 27,500 shares in the company, valued at approximately $1,096,150. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,291 shares of company stock worth $962,766. Insiders own 6.70% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.